GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChemoCentryx Inc (NAS:CCXI) » Definitions » Days Payable

ChemoCentryx (ChemoCentryx) Days Payable : 739.49 (As of Jun. 2022)


View and export this data going back to 2012. Start your Free Trial

What is ChemoCentryx Days Payable?

ChemoCentryx's average Accounts Payable for the three months ended in Jun. 2022 was $6.51 Mil. ChemoCentryx's Cost of Goods Sold for the three months ended in Jun. 2022 was $0.80 Mil. Hence, ChemoCentryx's Days Payable for the three months ended in Jun. 2022 was 739.49.

The historical rank and industry rank for ChemoCentryx's Days Payable or its related term are showing as below:

CCXI' s Days Payable Range Over the Past 10 Years
Min: 2554.2   Med: 11857.06   Max: 11857.06
Current: 2554.2

During the past 13 years, ChemoCentryx's highest Days Payable was 11857.06. The lowest was 2554.20. And the median was 11857.06.

CCXI's Days Payable is not ranked
in the Biotechnology industry.
Industry Median: 148.78 vs CCXI: 2554.20

ChemoCentryx's Days Payable increased from Jun. 2021 (0.00) to Jun. 2022 (739.49). It may suggest that ChemoCentryx delayed paying its suppliers.


ChemoCentryx Days Payable Historical Data

The historical data trend for ChemoCentryx's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoCentryx Days Payable Chart

ChemoCentryx Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 11,857.06

ChemoCentryx Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 2,708.34 739.49

Competitive Comparison of ChemoCentryx's Days Payable

For the Biotechnology subindustry, ChemoCentryx's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChemoCentryx's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ChemoCentryx's Days Payable distribution charts can be found below:

* The bar in red indicates where ChemoCentryx's Days Payable falls into.



ChemoCentryx Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

ChemoCentryx's Days Payable for the fiscal year that ended in Dec. 2021 is calculated as

Days Payable (A: Dec. 2021 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2020 ) + Accounts Payable (A: Dec. 2021 )) / count ) / Cost of Goods Sold (A: Dec. 2021 )*Days in Period
=( (12.875 + 6.746) / 2 ) / 0.302*365
=9.8105 / 0.302*365
=11,857.06

ChemoCentryx's Days Payable for the quarter that ended in Jun. 2022 is calculated as:

Days Payable (Q: Jun. 2022 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Mar. 2022 ) + Accounts Payable (Q: Jun. 2022 )) / count ) / Cost of Goods Sold (Q: Jun. 2022 )*Days in Period
=( (5.423 + 7.592) / 2 ) / 0.803*365 / 4
=6.5075 / 0.803*365 / 4
=739.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ChemoCentryx Days Payable Related Terms

Thank you for viewing the detailed overview of ChemoCentryx's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


ChemoCentryx (ChemoCentryx) Business Description

Traded in Other Exchanges
N/A
Address
835 Industrial Road, Suite 600, San Carlos, CA, USA, 94070
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
Executives
Susan M Kanaya officer: SVP Finance, CFO & Secretary 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Thomas J. Schall director, 10 percent owner, officer: President, CEO and Director 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Jennifer Lyn Herron director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Yi Ching Yau officer: SVP, Finance & Acctg Officer C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Tausif Butt officer: EVP, Chief Operating Officer C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Thomas A. Edwards director C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Markus J. Cappel officer: CBO and Treasurer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Pui San Kwan officer: Principal Acctg Officer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Rajinder Singh officer: SVP, Research C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027